Drugs / hCT-MSCs
hCT-MSCs
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04549285 | Mar 2021 → Feb 2022 | COVID-19–associated multisystem inflammatory syndrome in children | Joanne Kurtzberg, MD | Withdrawn | No outcome recorded Stop: Enrollment |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | hCT-MSCs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04549285 ↗ |
| Known as | hCT-MSC | “Human Cord Tissue Mesenchymal Stromal Cells (hCT-MSCs)” NCT04549285 ↗ |
| Known as | Human Cord Tissue Mesenchymal Stromal Cells | “Human Cord Tissue Mesenchymal Stromal Cells (hCT-MSCs)” NCT04549285 ↗ |
| Known as | Human Umbilical Cord Tissue-derived Mesenchymal Stromal Cells | “Human Umbilical Cord Tissue-derived Mesenchymal Stromal Cells (hCT-MSC):” NCT04549285 ↗ |
| Modality | Cell therapy | “hCT-MSCs is an allogeneic cell product manufactured from donated umbilical cord tissue” NCT04549285 ↗ |
| Route | Intravenous | “The hCT-MSCs will be administered intravenously over 30-60 minutes via a syringe pump.” NCT04549285 ↗ |